Literature DB >> 17579360

A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region.

Willy Lissens1, Alessia Arena, Sara Seneca, Mohammad Rafi, Giovanni Sorge, Inge Liebaers, David Wenger, Agata Fiumara.   

Abstract

A high proportion of patients with late onset forms of Krabbe disease is observed in a region north of Catania in Sicily. Molecular analysis in five families from this region shows that this condition is mainly due to a not previously described p.Gly41Ser substitution in the GALC gene that abolishes catalytic activity of the galactocerebrosidase enzyme, as shown by expression studies. Three patients were homozygous for this mutation, the other two were heterozygous, one with a frameshift mutation and one with a missense mutation on the second allele. Therefore, the mutation must be a mild one since it leads to late onset disease in all patients. In addition, it is on a unique haplotype indicating that it represents a founder mutation. This is also supported by the fact that the mutation was not found in three late onset patients from other regions in Sicily, in whom four novel mutations were identified. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579360     DOI: 10.1002/humu.9500

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease.

Authors:  Dae Song Jang; Wenjuan Ye; Tian Guimei; Melani Solomon; Noel Southall; Xin Hu; Juan Marugan; Marc Ferrer; Gustavo H B Maegawa
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 2.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Authors:  James D Weisfeld-Adams; Ilana B Katz Sand; Justin M Honce; Fred D Lublin
Journal:  Brain       Date:  2015-01-29       Impact factor: 13.501

Review 4.  Krabbe Disease in the Arab World.

Authors:  Hatem Zayed
Journal:  J Pediatr Genet       Date:  2015-03

Review 5.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

6.  Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease.

Authors:  Gregory B Potter; Marta Santos; Muriel T Davisson; David H Rowitch; Dan L Marks; Ernesto R Bongarzone; Magdalena A Petryniak
Journal:  Hum Mol Genet       Date:  2013-04-24       Impact factor: 6.150

7.  Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones.

Authors:  Wing C Lee; Dongcheul Kang; Ena Causevic; Aimee R Herdt; Elizabeth A Eckman; Christopher B Eckman
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

8.  Structural snapshots illustrate the catalytic cycle of β-galactocerebrosidase, the defective enzyme in Krabbe disease.

Authors:  Chris H Hill; Stephen C Graham; Randy J Read; Janet E Deane
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity.

Authors:  Daesung Shin; M Laura Feltri; Lawrence Wrabetz
Journal:  J Neurosci       Date:  2016-02-10       Impact factor: 6.167

10.  Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease.

Authors:  Barbara Tappino; Roberta Biancheri; Matthew Mort; Stefano Regis; Fabio Corsolini; Andrea Rossi; Marina Stroppiano; Susanna Lualdi; Agata Fiumara; Bruno Bembi; Maja Di Rocco; David N Cooper; Mirella Filocamo
Journal:  Hum Mutat       Date:  2010-12       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.